SCHEMBL212263

SCHEMBL212263

COC(=O)c1ccc2nc(N)sc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.71
CYP3A4 P08684 4/20 0.67
KCNH2 Q12809 1/20 0.67
CYP1A2 P05177 3/20 0.66
PIK3CA P42336 1/20 0.64
PIK3CB P42338 1/20 0.64
PIK3CG P48736 1/20 0.64
PI4KB Q9UBF8 1/20 0.64
NPC1 O15118 6/20 0.60
RAB9A P51151 6/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
LMNA P02545 3/20 0.60
MAPT P10636 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 1/20 0.60
TNF P01375 1/20 0.60
GAA P10253 1/20 0.60
HPGD P15428 1/20 0.60
NR2F2 P24468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1121708 0.88 CYP3A4 (0.57) CYP2C9CYP3A4KCNH2CYP1A2PIK3CA
SCHEMBL1177897 0.85 PIK3CA (0.60) CYP2C9CYP3A4KCNH2CYP1A2PIK3CA
SCHEMBL21177836 0.84 KIT (0.61) CYP2C9CYP3A4KCNH2CYP1A2NPC1
SCHEMBL73574 0.84 RAB9A (0.65) CYP2C9CYP3A4KCNH2CYP1A2NPC1
SCHEMBL9722783 0.84 KIT (0.58) CYP2C9CYP3A4KCNH2CYP1A2PIK3CA
SCHEMBL9722788 0.84 CYP2C9 (0.60) CYP2C9CYP3A4KCNH2CYP1A2PIK3CA
SCHEMBL16809339 0.83 RAB9A (0.76) PIK3CAPIK3CBPIK3CGPI4KBNPC1
SCHEMBL1980717 0.83 PIK3CA (0.66) CYP2C9PIK3CAPIK3CBPIK3CGPI4KB
SCHEMBL9722762 0.83 KIT (0.60) CYP2C9CYP3A4KCNH2CYP1A2NPC1
SCHEMBL1638828 0.83 RAB9A (0.59) CYP2C9CYP3A4CYP1A2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509470-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-12-30 US disclosed
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
WO-2025136887-A1 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2025-06-26 WO disclosed
CN-117126578-B Organosilicon polymer/POSS hybrid antifouling coating grafted with antibacterial molecules and preparation method thereof 中国科学院海洋研究所 2025-04-22 CN disclosed
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2025-04-10 US disclosed
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 US disclosed
WO-2025040743-A1 CONJUGATED TLR7 AND RIG-I AGONISTS UNIVERZA V LJUBLJANI (SI) 2025-02-27 WO disclosed
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders ARDELYX, INC. (US) 2025-01-28 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
CN-118660885-A Norbornene analogs and their use as potentiators of antitubercular drugs 国家医疗保健研究所 2024-09-17 CN disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
US-5120872-A Textile dyeing CIBA-GEIGY CORPORATION (US) 1992-06-09 US disclosed
US-4994563-A Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness CIBA-GEIGY CORPORATION (US) 1991-02-19 US disclosed
EP-0349486-A2 Azo dyes, their preparation and their use CIBA-GEIGY AG (CH) 1990-01-03 EP disclosed
US-4424155-A 3-AMINO-1,2,4-OXADIAZOL-5-YL DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1984-01-03 US disclosed
US-4041025-A FOR HYDROPHOBIC FIBERS SUCH AS POLYESTERS, YELLOW TO BLUE-GREEN SHADES BASF AKTIENGESELLSCHAFT (DT) 1977-08-09 US disclosed
US-4041024-A FOR POLYAMIDES AND POLYURETHANES BAYER AKTIENGESELLSCHAFT (DT) 1977-08-09 US disclosed
US-3974123-A Dyes for thermoplastics BASF AKTIENGESELLSCHAFT (DT) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509470-B2 Antiviral heterocyclic compounds NR3C1, ZC3HAV1, HAVCR2 CYP2C9 2358/4885CYP3A4 1089/4885KCNH2 2640/4885
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 CYP2C9 806/4885CYP3A4 343/4885KCNH2 4155/4885
US-12209088-B2 Hormone receptor modulators for treating metabolic conditions and disorders NR1H4, FXR1, GLP1R CYP2C9 1237/4885CYP3A4 878/4885KCNH2 4252/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 CYP2C9 4831/4885CYP3A4 4740/4885KCNH2 4402/4885
US-20250115608-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS NR1H4, FXR1, GLP1R CYP2C9 1237/4885CYP3A4 878/4885KCNH2 4252/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B CYP2C9 391/4885CYP3A4 587/4885KCNH2 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.